Aktis Oncology Files for IPO to Raise Up to $316.4M to Advance Radiopharmaceutical Pipeline

summarizeSummary

Aktis Oncology, a clinical-stage biotech, is pursuing an IPO to raise up to $316.4 million, including a $100 million indicated interest from Eli Lilly, to fund its radiopharmaceutical pipeline and extend its cash runway into 2029.

check_boxKey Events

• Initial Public Offering (IPO)

  Aktis Oncology, Inc. filed an S-1/A registration statement for an IPO of 17,650,000 shares of common stock, with an expected price range of $16.00 to $18.00 per share. This follows a one-for-3.8044 reverse stock split.

• Significant Capital Raise

  The offering is expected to generate net proceeds of approximately $274.5 million (at the midpoint of the price range) or up to $316.4 million if underwriters exercise their option to purchase additional shares.

• Eli Lilly's Strategic Investment

  Eli Lilly and Company, an existing stockholder, has indicated interest in purchasing approximately $100.0 million in shares in the offering, signaling strong institutional confidence in Aktis Oncology's platform.

• Pipeline Advancement

  Proceeds will primarily fund the ongoing Phase 1b trial of [225Ac]Ac-AKY-1189 for Nectin-4 expressing tumors and advance [225Ac]Ac-AKY-2519 into a Phase 1b clinical trial for B7-H3 expressing tumors.

auto_awesomeAnalysis

Aktis Oncology, Inc.'s S-1/A filing for an Initial Public Offering (IPO) is a critical financing event, poised to provide substantial capital for the clinical-stage oncology company. The expected net proceeds of up to $316.4 million, combined with existing cash, are projected to extend the company's operational runway into 2029. This funding is essential for advancing its lead radiopharmaceutical candidate, [225Ac]Ac-AKY-1189, through its Phase 1b clinical trial for Nectin-4 expressing tumors, and progressing [225Ac]Ac-AKY-2519 into Phase 1b studies for B7-H3 expressing tumors. The indicated interest from Eli Lilly and Company to purchase $100.0 million in shares further validates Aktis Oncology's novel miniprotein radioconjugate platform and pipeline. While the offering will result in significant dilution for new investors, it secures vital capital for a pre-revenue biotech company operating in a high-risk, high-reward sector.